PharmGKB summary: very important pharmacogene information for G6PD

Glucose-6-phosphate dehydrogenase (G6PD) was one of the first genes found to be associated with variable drug response. It is also very polymorphic, with G6PD deficiency found in more than 300 million people worldwide [1]. Here, we provide an overview of G6PD as a very important pharmacogene, and detail genetic variants and haplotypes associated with drug response (Although most G6PD variants are caused by single nucleotide polymorphisms (SNPs) in the coding region of the G6PD gene at the X chromosome, due to the heterogeneity of alleles causing G6PD deficiency; here, we use the term ‘haplotype’ to define the set of linked SNPs in a G6PD variant that are inherited together and that may or may not produce G6PD deficiency). A more in-depth report, with interactive links to individual literature annotations, can be found at http://www.pharmgkb.org/gene/PA28469.

[1]  B. Migeon,et al.  Localization of loci for hypoxanthine phosphoribosyltransferase and glucose-6-phosphate dehydrogenase and biochemical evidence of nonrandom X chromosome expression from studies of a human X-autosome translocation. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Luzzatto,et al.  Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant. , 1972, Lancet.

[3]  L. Botigué,et al.  G6PD Deficient Alleles and Haplotype Analysis of Human G6PD Locus in São Tomé e Príncipe (West Africa) , 2007, Human biology.

[4]  David Schellenberg,et al.  A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics , 2011, PLoS medicine.

[5]  Ernest Beutler,et al.  The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. , 2009, Blood cells, molecules & diseases.

[6]  H. Fujii,et al.  A single mutation 202G>A in the human glucose-6-phosphate dehydrogenase gene (G6PD) can cause acute hemolysis by itself. , 2002, Blood.

[7]  E. Beutler,et al.  Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Mancuso,et al.  p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase , 2011, Nature Cell Biology.

[9]  G. Battistuzzi,et al.  Glucose-6-phosphate dehydrogenase. , 1985, Advances in human genetics.

[10]  D. Swallow,et al.  Protein Dysfunction in Human Genetic Disease , 1997 .

[11]  F. Esamai,et al.  Chlorproguanil−Dapsone−Artesunate versus Artemether−Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria , 2009, PloS one.

[12]  R. Ravazzolo,et al.  Haemolytic Effect of Two Sulphonamides Evaluated by a New Method , 1976, British journal of haematology.

[13]  B. Ramot,et al.  Haemolytic jaundice following aspirin administration to a patient with a deficiency of glucose-6-phosphate dehydrogenase in erythrocytes. , 1960, Acta haematologica.

[14]  Y. Amitai,et al.  Glucose-6-phosphate dehydrogenase deficiency severely restricts the biotransformation of daunorubicin in human erythrocytes. , 1996, The Journal of laboratory and clinical medicine.

[15]  M. D'urso,et al.  Structural analysis of the X‐linked gene encoding human glucose 6‐phosphate dehydrogenase. , 1986, The EMBO journal.

[16]  M. Totani,et al.  [Glucose-6-phosphate dehydrogenase]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[17]  E. Beutler,et al.  The NT 1311 polymorphism of G6PD: G6PD Mediterranean mutation may have originated independently in Europe and Asia. , 1990, American journal of human genetics.

[18]  Virgil F. Fairbanks,et al.  THE NORMAL HUMAN FEMALE AS A MOSAIC OF X-CHROMOSOME ACTIVITY: STUDIES USING THE GENE FOR G-6-PD-DEFICIENCY AS A MARKER , 1962 .

[19]  R. Kletzien,et al.  Glucose‐6‐phosphate dehydrogenase: a “housekeeping” enzyme subject to tissue‐specific regulation by hormones, nutrients, and oxidant stress , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  H. Fujii,et al.  Distribution of glucose-6-phosphate dehydrogenase mutations in Southeast Asia , 2001, Human Genetics.

[21]  H. Jörnvall,et al.  Glucose-6-phosphate dehydrogenase. Characteristics revealed by the rat liver enzyme structure. , 1989, European journal of biochemistry.

[22]  O. Müller,et al.  Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841] , 2005, Malaria Journal.

[23]  T. Vulliamy,et al.  Polymorphic sites in the African population detected by sequence analysis of the glucose-6-phosphate dehydrogenase gene outline the evolution of the variants A and A-. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Beutler,et al.  Human red cell glucose-6-phosphate dehydrogenase: All active enzyme has sequence predicted by the X chromosome-encoded cDNA , 1990, Cell.

[25]  Tizhen Yan,et al.  Incidence and complete molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Guangxi Zhuang autonomous region of southern China: description of four novel mutations. , 2006, Haematologica.

[26]  L. Luzzatto,et al.  Genetic variants of human erythrocyte glucose-6-phosphate dehydrogenase. Kinetic and thermodynamic parameters of variants A, B, and A- in relation to quaternary structure. , 1976, The Journal of biological chemistry.

[27]  Kounosuke Watabe,et al.  Metabolic genes in cancer: their roles in tumor progression and clinical implications. , 2010, Biochimica et biophysica acta.

[28]  J. Bautista,et al.  G6PD deficiency: the genotype-phenotype association. , 2007, Blood reviews.

[29]  Klaus Lindpaintner,et al.  Pharmacogenetics and pharmacogenomics. , 2005, Methods in molecular medicine.

[30]  M. D'urso,et al.  Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5' non-coding region. , 1986, Nucleic acids research.

[31]  E. Beutler,et al.  Molecular genetics of the glucose-6-phosphate dehydrogenase (G6PD) Mediterranean variant and description of a new G6PD mutant, G6PD Andalus1361A. , 1990, American journal of human genetics.

[32]  L. Luzzatto The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics , 2010, The Lancet.

[33]  B. Glader Evaluation of the hemolytic role of aspirin in glucose-6-phosphate dehydrogenase deficiency. , 1976, The Journal of pediatrics.

[34]  E. Andrès,et al.  Glibenclamide-induced acute haemolytic anaemia revealing a G6PD-deficiency. , 2004, Diabetes research and clinical practice.

[35]  P. Rosenthal,et al.  Impact of the Method of G6PD Deficiency Assessment on Genetic Association Studies of Malaria Susceptibility , 2009, PloS one.

[36]  E. Beutler,et al.  Alternative splicing of human glucose-6-phosphate dehydrogenase messenger RNA in different tissues. , 1989, The Journal of clinical investigation.

[37]  E. Beutler,et al.  Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency. , 1971, Annals of internal medicine.

[38]  A. Yoshida,et al.  A single nucleotide base transition is the basis of the common human glucose-6-phosphate dehydrogenase variant A (+). , 1987, Genomics.

[39]  Z. Spolarics,et al.  Endotoxemia, pentose cycle, and the oxidant/antioxidant balance in the hepatic sinusoid , 1998, Journal of leukocyte biology.

[40]  H. Notopuro,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.

[41]  O. Doumbo,et al.  X-Linked G6PD Deficiency Protects Hemizygous Males but Not Heterozygous Females against Severe Malaria , 2007, PLoS medicine.

[42]  B. M. Greenwood,et al.  Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria , 1995, Nature.

[43]  A. Motulsky,et al.  Human glucose-6-phosphate dehydrogenase variants. , 1971, Bulletin of the World Health Organization.

[44]  C. Naylor,et al.  Amino acid substitutions at the dimer interface of human glucose-6-phosphate dehydrogenase that increase thermostability and reduce the stabilising effect of NADP. , 1998, European journal of biochemistry.

[45]  R. J. Dern,et al.  A new structural variant of glucose-6-phosphate dehydrogenase with a high production rate (G6PD Hektoen). , 1969, The Journal of laboratory and clinical medicine.

[46]  T. Vulliamy,et al.  G6PD Canton a common deficient variant in South East Asia caused by a 459 Arg----Leu mutation. , 1990, Nucleic acids research.

[47]  A. Yoshida,et al.  A single amino Acid substitution (asparagine to aspartic Acid) between normal (b+) and the common negro variant (a+) of human glucose-6-phosphate dehydrogenase. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Au,et al.  Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. , 2000, Structure.

[49]  M. Rosemeyer,et al.  Subunit interactions of glucose-6-phosphate dehydrogenase from human erythrocytes. , 1969, European journal of biochemistry.

[50]  T. Ikuta,et al.  Human glucose-6-phosphate dehydrogenase: primary structure and cDNA cloning. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[51]  T. Bousema,et al.  In Tanzania, Hemolysis after a Single Dose of Primaquine Coadministered with an Artemisinin Is Not Restricted to Glucose-6-Phosphate Dehydrogenase-Deficient (G6PD A−) Individuals , 2010, Antimicrobial Agents and Chemotherapy.

[52]  E. Beutler,et al.  The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker. , 1962, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Sagone,et al.  The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes , 1979, American journal of hematology.

[54]  P. Pandolfi,et al.  Targeted disruption of the housekeeping gene encoding glucose 6‐phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. , 1995, The EMBO journal.

[55]  M. Cappellini,et al.  G6PD Ferrara I has the same two mutations as G6PD A(-) but a distinct biochemical phenotype , 1994, Human Genetics.

[56]  M. Rowland,et al.  The Impact of Phenotypic and Genotypic G6PD Deficiency on Risk of Plasmodium vivax Infection: A Case-Control Study amongst Afghan Refugees in Pakistan , 2010, PLoS medicine.

[57]  H. Frischer,et al.  Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU" [1,3-bis(chloroethyl)-1-nitrosourea]. , 1977, The Journal of laboratory and clinical medicine.

[58]  O. Müller,et al.  Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso , 2005, Tropical medicine & international health : TM & IH.

[59]  E. Beutler,et al.  Mutation analysis of glucose-6-phosphate dehydrogenase (G6PD) variants in Costa Rica , 1991, Human Genetics.

[60]  E. Beutler,et al.  The hemolytic effect of primaquine and related compounds: a review. , 1959, Blood.

[61]  C. Clayman,et al.  4. TOXICITY OF PRIMAQUINE IN NEGROES , 1952 .

[62]  T. Vulliamy,et al.  Glucose 6-phosphate dehydrogenase mutations causing enzyme deficiency in a model of the tertiary structure of the human enzyme. , 1996, Blood.

[63]  P. Carson,et al.  Enzymatic deficiency in primaquine-sensitive erythrocytes. , 1956, Science.

[64]  Charles Ja Medical care today. , 1949 .

[65]  M. Lacerda,et al.  Clinical aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian Amazon. , 2010, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[66]  J. Bautista,et al.  Stress response and cytoskeletal proteins involved in erythrocyte membrane remodeling upon Plasmodium falciparum invasion are differentially carbonylated in G6PD A- deficiency. , 2011, Free radical biology & medicine.

[67]  H. Levy,et al.  On the molecular weight of human glucose 6-phosphate dehydrogenase. , 1977, Biochemical and biophysical research communications.

[68]  T. Liu,et al.  Two commonly occurring nucleotide base substitutions in Chinese G6PD variants. , 1991, Biochemical and biophysical research communications.

[69]  L. Forman,et al.  Identification of the binding domain for NADP+ of human glucose-6-phosphate dehydrogenase by sequence analysis of mutants. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Prchal,et al.  Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood , 1989 .

[71]  L Luzzatto,et al.  Hematologically important mutations: glucose-6-phosphate dehydrogenase. , 1996, Blood cells, molecules & diseases.

[72]  T. Vulliamy,et al.  Human red cell glucose-6-phosphate dehydrogenase is encoded only on the X chromosome , 1990, Cell.

[73]  B. Tekwani,et al.  Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. , 2009, Toxicology and applied pharmacology.

[74]  A. Yoshida,et al.  5' structure and expression of human glucose-6-phosphate dehydrogenase mRNA. , 1993, DNA and Cell Biology.

[75]  T. Chan,et al.  Characteristics and distribution of glucose-6-phosphate dehydrogenase-deficient variants in South China. , 1972, American journal of human genetics.

[76]  M. Hammer,et al.  The Extent of Linkage Disequilibrium Caused by Selection on G6PD in Humans , 2005, Genetics.

[77]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[78]  H. Kirkman,et al.  A Chinese variant of glucose-6-phosphate dehydrogenase. , 1966, The Journal of laboratory and clinical medicine.

[79]  B. Bain A ghostly presence—G6PD deficiency , 2010, American journal of hematology/oncology.

[80]  Kwaku Poku Asante,et al.  An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria , 2008, PloS one.

[81]  M. Berkovitch,et al.  Medications and Glucose-6-Phosphate Dehydrogenase Deficiency , 2010, Drug safety.

[82]  D. Labie,et al.  HÆMOGLOBINOPATHIES AND G.-6-P.D. DEFICIENCY IN LAOS , 1978, The Lancet.

[83]  F. Gómez-Gallego,et al.  Structural Defects Underlying Protein Dysfunction in Human Glucose-6-phosphate Dehydrogenase A− Deficiency* , 2000, The Journal of Biological Chemistry.

[84]  L. Manco,et al.  Chronic hemolytic anemia is associated with a new glucose-6-phosphate dehydrogenase in-frame deletion in an older woman. , 2011, Blood cells, molecules & diseases.

[85]  A. Yoshida,et al.  Amino acid substitution (histidine to tyrosine) in a glucose-6-phosphate dehydrogenase variant (G6PD Hektoen) associated with over-production. , 1970, Journal of molecular biology.

[86]  C. Clayman,et al.  Toxicity of primaquine in Caucasians. , 1952, Journal of the American Medical Association.

[87]  J. A. Kruse,et al.  Hemolysis and Methemoglobinemia Secondary to Rasburicase Administration , 2005, The Annals of pharmacotherapy.

[88]  J. Spivak,et al.  Commentary on and reprint of Beutler E, Yeh M, Fairbanks VF, The normal human female as a mosaic of X-chromosome activity: Studies using the gene for G-6-PD-deficiency as a marker, in Proceedings of the National Academy of Sciences (1962) 48:9–16 , 2000 .

[89]  A. Gbakima,et al.  G6PD deficiency assessment in Freetown, Sierra Leone, reveals further insight into the molecular heterogeneity of G6PD A- , 2008, Journal of Human Genetics.

[90]  J. Stockman,et al.  Aspirin-induced Hemolysis: The Role of Concomitant Oxidant (H2O2) Challenge , 1978, Pediatric Research.

[91]  T. Vulliamy,et al.  Variants of glucose‐6‐phosphate dehydrogenase are due to missense mutations spread throughout the coding region of the gene , 1993, Human mutation.

[92]  A. Yoshida,et al.  A glucose-6-phosphate dehydrogenase variant, Gd(-) Santamaria found in Costa Rica. , 1984, Acta haematologica.

[93]  D. Toniolo,et al.  Two point mutations are responsible for G6PD polymorphism in Sardinia. , 1989, American journal of human genetics.

[94]  R. Khesin,et al.  Molecular Genetics , 1968, Springer Berlin Heidelberg.

[95]  C. Clayman,et al.  Toxicity of primaquine in Negroes. , 1952, Journal of the American Medical Association.

[96]  T. Meloni,et al.  Glyburide‐induced acute haemolysis in a G6PD‐deficient patient with NIDDM , 1996, British journal of haematology.

[97]  C. Clayman,et al.  3. TOXICITY OF PRIMAQUINE IN CAUCASIANS , 1952 .

[98]  L. Luzzatto,et al.  Red cell glucose‐6‐phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population , 2000, Tropical medicine & international health : TM & IH.

[99]  A. Ghafary,et al.  Drug-induced haemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Afghanistan. , 1990, Annals of tropical paediatrics.

[100]  G. Forteleoni,et al.  Aspirin-induced acute haemolytic anaemia in glucose-6-phosphate dehydrogenase-deficient children with systemic arthritis. , 1989, Acta haematologica.

[101]  J. Kublin,et al.  Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial , 2004, The Lancet.

[102]  G. D. Campbell,et al.  Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. , 1975, Annals of internal medicine.

[103]  M. D'urso,et al.  Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[104]  C. Karema,et al.  High Risk of Severe Anaemia after Chlorproguanil-Dapsone+Artesunate Antimalarial Treatment in Patients with G6PD (A-) Deficiency , 2008, PloS one.

[105]  A. Gehani,et al.  [G6PD deficiency]. , 1974, Xianggang hu li za zhi. The Hong Kong nursing journal.

[106]  G. Brittenham,et al.  Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand. , 2006, The Korean journal of parasitology.

[107]  Pardis C Sabeti,et al.  Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility , 2009, European Journal of Human Genetics.

[108]  Y. Kan,et al.  Two structural genes on different chromosomes are required for encoding the major subunit of human red cell glucose-6-phosphate dehydrogenase , 1989, Cell.

[109]  L. Luzzatto Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. , 2006, Haematologica.

[110]  M. D'urso,et al.  Common glucose‐6‐phosphate dehydrogenase (G6PD) variants from the Italian population: biochemical and molecular characterization , 1990, Annals of human genetics.